105 related articles for article (PubMed ID: 1465666)
1. [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus].
Ilić RS; Mihailović D
Srp Arh Celok Lek; 1992; 120(3-4):97-9. PubMed ID: 1465666
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
Shigemasa K; Hiura M; Ioka A; Yokoyama T; Nogawa T; Chiba T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):256-7. PubMed ID: 8492013
[No Abstract] [Full Text] [Related]
3. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
4. [Serum CA 125 and TPA determination in malignant neoplasms of the uterus].
Gadducci A; Facchini V; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1988; 109(3):151-5. PubMed ID: 3207319
[No Abstract] [Full Text] [Related]
5. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
[TBL] [Abstract][Full Text] [Related]
6. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
7. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Schauenstein E; Lahousen M; Weblacher M; Steinschifter W; Estelberger W; Schauenstein K
Cancer; 1996 Aug; 78(3):511-6. PubMed ID: 8697398
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
9. [Relations between markers and immunological status in surgical patients. Tumor markers and immunity in surgery].
Nano M; Ricci E; Pecchio F; Rapellino M; Giaccone M; Molaschi M
Minerva Med; 1988 Nov; 79(11):943-6. PubMed ID: 3200471
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Schalken J
Eur Urol; 2007 Dec; 52(6):1679. PubMed ID: 17306439
[No Abstract] [Full Text] [Related]
12. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
Chen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
15. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125 as a marker for patients with external endometriosis.
Takahashi K; Kijima S; Yoshino K; Shibukawa T; Kitao M
Int J Fertil; 1989; 34(2):143-8. PubMed ID: 2565317
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of gynaecologic tumour markers.
Halila H; Alfthan H; Stenman UH
Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of tumor markers levels in determination of surgical procedure in patients with gallbladder carcinoma.
Stefanović D; Novaković R; Perisić-Savić M; Djordjević Z; Zivanović M; Stajić S
Med Pregl; 1993; 46 Suppl 1():58-9. PubMed ID: 8569609
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
